GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (NAS:AVEO) » Definitions » Cyclically Adjusted Price-to-FCF

AVEO Pharmaceuticals (AVEO Pharmaceuticals) Cyclically Adjusted Price-to-FCF : (As of May. 06, 2024)


View and export this data going back to 2010. Start your Free Trial

What is AVEO Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


AVEO Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for AVEO Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVEO Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

AVEO Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AVEO Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AVEO Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, AVEO Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVEO Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AVEO Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where AVEO Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



AVEO Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

AVEO Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2022 is calculated as:

For example, AVEO Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2022 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=0.006/125.2265*125.2265
=0.006

Current CPI (Sep. 2022) = 125.2265.

AVEO Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201212 -6.699 96.871 -8.660
201303 -4.530 98.209 -5.776
201306 -6.447 98.518 -8.195
201309 -4.531 98.790 -5.744
201312 -1.806 98.326 -2.300
201403 -5.340 99.695 -6.708
201406 -3.771 100.560 -4.696
201409 -1.747 100.428 -2.178
201412 -2.051 99.070 -2.593
201503 -3.005 99.621 -3.777
201506 -2.072 100.684 -2.577
201509 1.580 100.392 1.971
201512 0.002 99.792 0.003
201603 -1.774 100.470 -2.211
201606 -0.686 101.688 -0.845
201609 -1.147 101.861 -1.410
201612 -0.982 101.863 -1.207
201703 -0.709 102.862 -0.863
201706 -0.637 103.349 -0.772
201709 -0.252 104.136 -0.303
201712 -0.316 104.011 -0.380
201803 -0.548 105.290 -0.652
201806 -0.706 106.317 -0.832
201809 -0.234 106.507 -0.275
201812 -0.401 105.998 -0.474
201903 -0.637 107.251 -0.744
201906 -0.378 108.070 -0.438
201909 1.176 108.329 1.359
201912 -0.457 108.420 -0.528
202003 -0.733 108.902 -0.843
202006 -0.434 108.767 -0.500
202009 -0.233 109.815 -0.266
202012 -0.495 109.897 -0.564
202103 -0.668 111.754 -0.749
202106 -0.543 114.631 -0.593
202109 -0.235 115.734 -0.254
202112 -0.354 117.630 -0.377
202203 -0.238 121.301 -0.246
202206 -0.071 125.017 -0.071
202209 0.006 125.227 0.006

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AVEO Pharmaceuticals  (NAS:AVEO) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


AVEO Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of AVEO Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


AVEO Pharmaceuticals (AVEO Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
30 Winter Street, Boston, MA, USA, 02108
AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.
Executives
Jebediah Ledell officer: Chief Operating Officer C/O AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Michael P Bailey director, officer: President & CEO IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Michael Ferraresso officer: Chief Commercial Officer AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Kevin Joseph Cullen director AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Epperly Corinne director AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Forest Baskett 10 percent owner
Joshua Makower 10 percent owner 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Scott D Sandell 10 percent owner
Growth Equity Opportunities Iv, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Erick Lucera officer: Chief Financial Officer 138 THISTLE ROAD, NORTH ANDOVER MA 08145
Scarlett Spring director AVEO PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Peter J Barris 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202

AVEO Pharmaceuticals (AVEO Pharmaceuticals) Headlines

From GuruFocus

AVEO Oncology Stockholders Approve Acquisition by LG Chem

By Stock market mentor Stock market mentor 01-06-2023